In today's trading session, Gland Pharma shares demonstrated a positive trend, increasing by 2.25% to reach Rs 1810.70 at 09:18 am during the trading day. Gland Pharma is a constituent of the NIFTY MIDCAP 150 index.
According to Moneycontrol analysis, the market sentiment for Gland Pharma is very bullish as of today, potentially influencing investor behavior.
Financial Performance Overview
The following provides an overview of Gland Pharma's recent financial performance, offering insights into its revenue, profitability, and key financial metrics.
Consolidated Quarterly Performance:
| Heading | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|
| Revenue | Rs 1,537.45 Cr | Rs 1,401.71 Cr | Rs 1,405.83 Cr | Rs 1,384.05 Cr | Rs 1,424.91 Cr |
| Net Profit | Rs 192.42 Cr | Rs 143.76 Cr | Rs 163.53 Cr | Rs 204.69 Cr | Rs 186.54 Cr |
| EPS | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 |
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Revenue | Rs 3,462.88 Cr | Rs 4,400.71 Cr | Rs 3,624.60 Cr | Rs 5,664.72 Cr | Rs 5,616.50 Cr |
| Net Profit | Rs 996.96 Cr | Rs 1,211.66 Cr | Rs 781.04 Cr | Rs 772.46 Cr | Rs 698.53 Cr |
| EPS | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 |
| BVPS | 360.86 | 435.64 | 483.23 | 529.65 | 555.40 |
| ROE | 16.88 | 16.92 | 9.81 | 8.85 | 7.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
Standalone Financials
Income Statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|
| Sales | 4,116 | 4,167 | 3,616 | 4,400 | 3,462 |
| Other Income | 215 | 166 | 240 | 223 | 134 |
| Total Income | 4,331 | 4,334 | 3,856 | 4,624 | 3,597 |
| Total Expenditure | 2,842 | 2,920 | 2,801 | 3,000 | 2,259 |
| EBIT | 1,488 | 1,413 | 1,055 | 1,624 | 1,338 |
| Interest | 22 | 7 | 7 | 5 | 3 |
| Tax | 375 | 362 | 272 | 406 | 337 |
| Net Profit | 1,089 | 1,043 | 775 | 1,212 | 997 |
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|
| Sales | 1,030 | 1,010 | 1,062 | 1,012 | 1,174 |
| Other Income | 43 | 65 | 57 | 48 | 46 |
| Total Income | 1,074 | 1,075 | 1,120 | 1,060 | 1,221 |
| Total Expenditure | 679 | 663 | 740 | 759 | 784 |
| EBIT | 394 | 412 | 379 | 301 | 437 |
| Interest | 3 | 18 | 0 | 0 | 4 |
| Tax | 101 | 99 | 98 | 77 | 111 |
| Net Profit | 290 | 295 | 281 | 222 | 321 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|
| Operating Activities | 1,073 | 1,135 | 367 | 791 | 604 |
| Investing Activities | 1,578 | -2,923 | 1,208 | -1,010 | -1,524 |
| Financing Activities | -339 | -7 | 14 | 34 | 1,238 |
| Others | 4 | 6 | 3 | 3 | 3 |
| Net Cash Flow | 2,316 | -1,789 | 1,594 | -180 | 322 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|
| Share Capital | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 9,738 | 8,977 | 7,935 | 7,141 | 5,886 |
| Current Liabilities | 523 | 414 | 730 | 581 | 512 |
| Other Liabilities | 142 | 132 | 91 | 94 | 80 |
| Total Liabilities | 10,421 | 9,541 | 8,773 | 7,834 | 6,496 |
| Fixed Assets | 1,784 | 1,813 | 1,747 | 1,692 | 1,292 |
| Current Assets | 5,766 | 4,571 | 6,888 | 5,844 | 5,123 |
| Other Assets | 2,870 | 3,156 | 137 | 296 | 80 |
| Total Assets | 10,421 | 9,541 | 8,773 | 7,834 | 6,496 |
| Contingent Liabilities | 0 | 100 | 128 | 124 | 219 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|
| Basic EPS (Rs.) | 66.15 | 63.35 | 47.12 | 73.84 | 63.07 |
| Diluted Eps (Rs.) | 66.15 | 63.35 | 47.11 | 73.67 | 62.99 |
| Book Value /Share (Rs.) | 592.08 | 546.13 | 482.90 | 435.68 | 360.86 |
| Dividend/Share (Rs.) | 18.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 40.27 | 37.80 | 34.81 | 39.41 | 41.49 |
| Operating Margin (%) | 36.16 | 33.91 | 30.75 | 36.90 | 38.64 |
| Net Profit Margin (%) | 26.47 | 25.03 | 21.45 | 27.54 | 28.79 |
| Return on Equity (%) | 11.17 | 11.59 | 9.75 | 16.93 | 16.88 |
| ROCE (%) | 15.03 | 15.48 | 13.82 | 22.39 | 22.36 |
| Return On Assets (%) | 10.45 | 10.93 | 8.84 | 15.47 | 15.34 |
| Current Ratio (X) | 11.01 | 11.04 | 9.43 | 10.04 | 10.00 |
| Quick Ratio (X) | 8.62 | 7.99 | 6.77 | 8.01 | 7.51 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 72.59 | 200.87 | 169.82 | 331.03 | 392.34 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.44 | 0.61 | 53.30 |
| Inventory Turnover Ratio (X) | 1.26 | 1.14 | 1.10 | 1.66 | 2.72 |
| 3 Yr CAGR Sales (%) | -3.29 | 9.70 | 17.19 | 46.72 | 46.21 |
| 3 Yr CAGR Net Profit (%) | -5.18 | 2.30 | 0.19 | 63.78 | 76.21 |
| P/E (x) | 24.07 | 29.13 | 26.92 | 44.32 | 39.29 |
| P/B (x) | 2.69 | 3.37 | 2.63 | 7.50 | 6.87 |
| EV/EBITDA (x) | 14.36 | 18.24 | 13.61 | 29.19 | 26.12 |
| P/S (x) | 6.37 | 7.28 | 5.78 | 12.21 | 11.71 |
With Gland Pharma currently trading at Rs 1810.70, investors are closely monitoring its performance within the NIFTY MIDCAP 150 index.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
